4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a report on Friday, June 27th. Barclays cut their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group cut their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Bank of America cut their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Down 5.0%

Shares of NASDAQ:FDMT traded down $0.22 during trading on Thursday, hitting $4.10. 196,317 shares of the stock traded hands, compared to its average volume of 817,638. The company has a market cap of $189.72 million, a price-to-earnings ratio of -1.29 and a beta of 2.81. The company has a fifty day moving average price of $3.78 and a two-hundred day moving average price of $4.20. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. On average, equities research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently modified their holdings of the business. Millennium Management LLC grew its holdings in shares of 4D Molecular Therapeutics by 1,607.1% during the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after buying an additional 1,337,497 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth $532,000. Rhumbline Advisers grew its holdings in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after buying an additional 3,675 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of 4D Molecular Therapeutics by 139.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock worth $364,000 after buying an additional 38,031 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of 4D Molecular Therapeutics by 196.3% during the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock worth $1,749,000 after buying an additional 208,021 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.